Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.
Key facts
- Who runs it
- Università Vita-Salute San Raffaele
- Where
- Charlottesville and Oklahoma City, United StatesSee the 2 sitesAlso in 10 other countries, 30 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 2,000 people, planned
- Started
- 15 Apr 2019
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Acute normovolemic hemodilution
- Standard care
- Record updated
- 8 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Signed informed consent
- Any cardiac surgical intervention on CPB
- Elective surgery
Who cannot take part
- Emergency surgery
- Unstable Coronary Artery Disease: Recent (< 6 weeks) myocardial infarction, unstable angina, severe (> 70%) left main coronary artery stenosis
- Critical preoperative state (ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, hemodynamic instability, preoperative inotropes or IABP, preoperative severe acute renal failure (anuria or oliguria <10ml/hr.)
- Medical decision (e.g.: planned pre-CPB ANH considered undeniable for ethical reasons or not applicable for safety issues)
- Pregnancy
- Unfeasibility to withdraw ≥ 650 ml without inducing hemodynamic instability
- Unfeasibility to withdraw ≥ 650 ml without inducing pre-CPB anemia (Htc <30%)
- Unfeasibility to withdraw ≥ 650 ml without inducing low Htc during CPB (Htc <24%)
Where in United States
Also in 10 other countries, 30 sites
- University of VirginiaCharlottesville, United States
- OUHSC - University of OklahomaOklahoma City, United States
About the trial
What the trial wants to find out
Transfusions are one of the most overused treatments in modern medicine, and saving blood is one important issue all around the world. Cardiac surgery makes up a large percentage of the overall blood components consumption in surgery.
Read full original descriptionShow less
Acute normovolemic hemo-dilution (ANH) is a well-known strategy which has been used for years without the support of high quality evidence based medicine to improve post-cardiopulmonary bypass coagulation and reduce red blood cells (RBC) transfusion. We designed a multicenter randomized controlled trial to investigate the effect of ANH in reducing the number of cardiac surgery patients receiving RBC transfusions during hospital stay. We will randomize 2000 patients to have sufficient power to demonstrate a 20% relative and 7% absolute risk reduction in the number of patients' RBC transfusion. If the results of the study will confirm our hypothesis, this will have a great impact on blood management in cardiac operating room.
The 2 groups in the trial
- ANHTreatment being tested
Best available treatments plus ANH, performed withdrawing a volume of blood before the CPB. The volume will be personalized for every patient, but it'll be at least 650ml.
Treatment: Acute normovolemic hemodilution
- Standard careOther group
No ANH
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Acute Normovolemic Hemodilution in High-risk Cardiac Surgery Patients. A Multicentre Randomized Trial.
- Record updated
- 8 May 2026